Loading stock data…
$11.10+0.05 (+0.45%)
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States.
Keros Therapeutics, Inc. in the Healthcare sector is trading at $11.10 with a market capitalization of $213M. Wall Street consensus targets $19.83 (6 analysts), implying a +78.7% move over the next 12 months. The stock is currently near its 52-week low of $9.69, remaining 11.1% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $367,000↓ | $385,000↓ | $14.26M↓ | $18.17M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$30.94M↓ | -$25.88M↑ | -$29.27M↓ | -$15.38M↑ | -$39.82M |
| Net Income | -$28.71M↓ | -$23.71M↓ | -$23.46M↓ | -$7.28M↑ | -$30.70M |
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the U...